Develops gene editing medicines for genetic diseases.
Jun 2026Revenue $47.0M/yrExpenses $123M/yr
No trendCash runway ≈ 1.8 years from Jun 2026
Figures by year
When will Editas Medicine be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $47.0M and expenses $123M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $40.5M | $201M | −$160M |
| Dec 2024 | $32.3M | $283M | −$251M |
| Dec 2023 | $78.1M | $247M | −$169M |
| Dec 2022 | $19.7M | $246M | −$226M |
| Dec 2021 | $25.5M | $219M | −$193M |
| Dec 2020 | $90.7M | $226M | −$135M |
| Dec 2019 | $20.5M | $161M | −$141M |
| Dec 2018 | $31.9M | $146M | −$114M |
| Dec 2017 | $13.7M | $134M | −$120M |
| Dec 2016 | $6.05M | $103M | −$97.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.